 |
 |
| |
|
|
| |
Artificial Intelligence is not something from the future. It is already here. AI is embedding roots in every industry and healthcare is not far behind. As AI penetrates various areas of healthcare, from diagnosis and treatment to administrative tasks, the demand for deep market research is greater than before. Healthcare market research - qualitative and quantitative, plays a key role in understanding the complex processes of this ever-changing environment.
The combination of AI-based solutions, electronic health records, and telemedicine is changing patient-provider relationships, while medical device market research is revealing opportunities for innovation to improve the outcomes of medical equipment and devices. As the healthcare industry navigates this transformation, insights from in-depth healthcare market research will pave the way for more informed decisions that will further improve patient outcomes, and operational efficiency, and ensure seamless integration of healthcare capabilities.
Acuity Life Sciences and Healthcare keeps track of all the technological advancements in healthcare and life sciences that may significantly impact the industry.
Manish Chandna – Director and Global Head, Consulting and Corporates
|
|
| |
|
|
|
Fresh and unique: Hand-picked content carefully curated for you
|
|
| |
|
|
|
|
The Evolution and Impact of Pharmaceutical Market Research
|
|
Advancements in cardiac devices and their impact on cardiovascular diseases
|
 |
|
 |
|
|
|
The insight paper focuses on the changing landscape of pharmaceutical market research, the integration of artificial intelligence, modern research methodologies, real-world applications, and the future of this dynamic field
|
|
The blog focuses on current advancements in cardiac devices and their impact on the diagnosis and treatment of cardiovascular diseases.
|
|
|
|
|
|
| |
|
|
|
|
FDA recently approved Novartis and Roche’s Xolair which prevents severe outcomes from common food allergies
|
|
US-based biotech startup Kelonia and Japan's Astellas Pharma finalized oncology deal worth $800 Mn
|
 |
|
 |
|
|
|
Xolair (omalizumab) is the first medicine that is known to reduce allergic reactions that can occur with accidental exposure to certain foods. The drug is approved for certain adults and children aged 1 year or older with certain allergies.
|
|
Under the agreement, the companies will combine Kelonia's iGPS with Xyphos’ (a wholly owned subsidiary of Astellas) ACCEL technology to develop novel in vivo CAR-T Cell therapies targeting up to two programmes.
|
|
|
|
|
|
|
| |
|
|
|
|
World Health Organization (WHO) issued new guidance on the ethics and governance of artificial intelligence (AI) for health, focusing on large multimodal models (LMMs)
|
|
Merck’s Animal Health division acquires Elanco’s Aqua Business
|
 |
|
 |
|
|
|
The WHO summarized the broad applications of LMMs in the healthcare industry which includes recommendations for governments, which set standards for the development and deployment of LMMs.
|
|
This acquisition will enhance Merck Animal Health’s aqua portfolio with products, such as CLYNAV®, a DNA-based vaccine that protects Atlantic salmon against pancreas disease, and IMVIXA®, an anti-parasitic sea lice treatment.
|
|
|
|
|
|
|
| |
|
|
|
Services offered by Acuity
|
|
| |
|
|
|
|
Healthcare market intelligence |
|
Pharma market intelligence
|
 |
|
 |
|
|
|
Acuity’s healthcare market intelligence programmes enable healthcare innovators to do so with actionable technical and commercial insights based on scientific proof and opinions of key leaders.
Acuity provides healthcare consulting services and healthcare competitive intelligence from the perspective of healthcare professionals, covering products and services that support healthcare workers and administrators.
|
|
Acuity’s team of subject-matter experts and significant expertise in strategic research and analysis, along with deep sector knowledge, have helped global pharma consulting and corporate clients implement tactical projects.
Acuity conducts specialized research within the pharma space and support clients in areas such as clinical trial analysis, competitive benchmarking, pharma market intelligence, pipeline analysis, mergers and acquisitions, due diligence, strategic analysis, pharma market research, pharmaceutical competitive intelligence, pharma forecasting, sales by indication, drug launch, opportunity assessment and go-to-market strategic projects.
|
|
|
|
|
|
| |
|
|
| |
How Acuity Knowledge Partners can help
|
|
| |
|
|
| |
Acuity Knowledge Partners (Acuity) is a leading provider of high-value research, analytics and business intelligence services to life sciences, biopharma, MedTech and healthcare consulting firms. We provide bespoke research support on market entry and due diligence, portfolio management, licensing and acquisition, go-to-market strategy, opportunity assessment, regulatory landscaping, product launch analysis, market access and therapy area assessment, indication prioritization, market research and forecasting, pipeline analysis and benchmarking and competitive intelligence.
|
|
| | | |
| |
| | |
| | |
ABOUT ACUITY KNOWLEDGE PARTNERS
Acuity Knowledge Partners (Acuity) is a leading provider of bespoke research, analytics and technology solutions to the financial services sector, including asset managers, corporate and investment banks, private equity and venture capital firms, hedge funds and consulting firms. Its global network of over 6,000 analysts and industry experts, combined with proprietary technology, supports more than 500 financial institutions and consulting companies to operate more efficiently and unlock their human capital, driving revenue higher and transforming operations. Acuity is headquartered in London and operates from 10 locations worldwide.
Acuity was established as a separate business from Moody’s Corporation in 2019, following its acquisition by Equistone Partners Europe (Equistone). In January 2023, funds advised by global private equity firm Permira acquired a majority stake in the business from Equistone, which remains invested as a minority shareholder.
For more information, visit www.acuitykp.com
|
|
| | | | | | US: +1 929 618 0217 | UK: +44 20 7550 4499 | India: +91 80 6113 3000
Sri Lanka: +94 11 235 6000 | Beijing: +86 10 8248 6812 | HK: +852 (972) 836-39 | contact@acuitykp.com | |
| | | |
| | | | | | ©2024 Acuity Knowledge Partners. All rights reserved. | |
| | | |
| |